The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
 
Shigenori Kadowaki
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takashi Ura
No Relationships to Disclose
 
Seiichiro Mitani
Honoraria - Merck Serono
 
Yukiya Narita
No Relationships to Disclose
 
Kyoko Kato
No Relationships to Disclose
 
Kazunori Honda
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst); Takeda (Inst)
 
Masashi Ando
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha